These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3116357)

  • 1. Beneficial actions of RO 15-1788, a benzodiazepine receptor antagonist, in hemorrhagic shock.
    Bitterman H; Lefer DJ; Lefer AM
    Methods Find Exp Clin Pharmacol; 1987 Jun; 9(6):341-7. PubMed ID: 3116357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial actions of antagonism of peptide leukotrienes in hemorrhagic shock.
    Bitterman H; Smith BA; Lefer AM
    Circ Shock; 1988 Mar; 24(3):159-68. PubMed ID: 3383353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
    Bitterman H; Yanagisawa A; Lefer AM
    Circ Shock; 1986; 20(1):1-11. PubMed ID: 2945667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock.
    Karasawa A; Rochester JA; Lefer AM
    Methods Find Exp Clin Pharmacol; 1990 May; 12(4):231-7. PubMed ID: 2165204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a role of platelet activating factor in hypovolemic shock in the rat.
    Zingarelli B; Squadrito F; Bussolino F; Calapai G; Altavilla D; Ioculano M; Campo GM; Canale P; Caputi AP
    J Lipid Mediat Cell Signal; 1994 Mar; 9(2):123-34. PubMed ID: 8012759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salutary consequences of blockade of platelet activating factor in hemorrhagic shock.
    Stahl GL; Bitterman H; Terashita Z; Lefer AM
    Eur J Pharmacol; 1988 May; 149(3):233-40. PubMed ID: 3409951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of hypertonic saline in the treatment of hemorrhagic shock.
    Bitterman H; Triolo J; Lefer AM
    Circ Shock; 1987; 21(4):271-83. PubMed ID: 3581442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxygen therapy in hemorrhagic shock.
    Bitterman H; Reissman P; Bitterman N; Melamed Y; Cohen L
    Circ Shock; 1991 Mar; 33(3):183-91. PubMed ID: 2044210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock.
    Bitterman H; Lefer DJ; Lefer AM
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jun; 337(6):679-86. PubMed ID: 3063971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective actions of S-nitroso-N-acetylpenicillamine (SNAP) in a rat model of hemorrhagic shock.
    Symington PA; Ma XL; Lefer AM
    Methods Find Exp Clin Pharmacol; 1992 Dec; 14(10):789-97. PubMed ID: 1338473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock.
    Bitterman H; Smith BA; Lefer AM
    Arzneimittelforschung; 1988 Oct; 38(10):1389-93. PubMed ID: 3196378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Involvement of platelet activating factors in pathologic leukocyte-endothelium interactions in the liver after hemorrhagic shock].
    Marzi I; Bauer M; Reisdorf E; Walcher F
    Zentralbl Chir; 1994; 119(11):814-21. PubMed ID: 7846961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of a new LTD4 antagonist (LY-171883) in traumatic shock.
    Hock CE; Lefer AM
    Circ Shock; 1985; 17(4):263-72. PubMed ID: 3841503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salutary effects of CG-4203, a novel, stable prostacyclin analog, in hemorrhagic shock.
    Bitterman H; Smith BA; Lefer DJ; Lefer AM
    J Cardiovasc Pharmacol; 1988 Sep; 12(3):293-9. PubMed ID: 2464101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-shock actions of a new converting enzyme inhibitor, enalaprilic acid, in hemorrhagic shock in cats.
    Freeman JG; Hock CE; Edmonds JS; Lefer AM
    J Pharmacol Exp Ther; 1984 Dec; 231(3):610-5. PubMed ID: 6094795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of PGE1 in hemorrhagic shock in rats.
    Bitterman H; Stahl GL; Terashita Z; Lefer AM
    Ann Emerg Med; 1988 May; 17(5):457-62. PubMed ID: 3364825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock.
    Aoki N; Johnson G; Siegfried MR; Lefer AM
    Eicosanoids; 1989; 2(3):169-74. PubMed ID: 2534278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
    Toth PD; Mikulaschek AW
    Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.
    Stahl GL; Bitterman H; Lefer AM
    Thromb Res; 1989 Feb; 53(3):327-38. PubMed ID: 2718150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actions of opiate antagonists with selective receptor interactions in hemorrhagic shock.
    Curtis MT; Lefer AM
    Circ Shock; 1983; 10(2):131-45. PubMed ID: 6301706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.